Very clever $CRVS amendment to Cohort 4 in atopic dermatitis trial beyond extending treatment with ITKi #soquelitinib to 8wks ⚡️Keeping dosing at 200mg BID allows Cohort 3+4 EASI data at 4 wks to be combined, doubling number of patients on SQL to N=24 and 4x PBO control⤵️

$CRVS oral #ITK inhibitor #soquelitinib Ph3 Peripheral T-cell Lymphoma: - #PTCL-NOS, follicular helper TCL, Systemic Anaplastic Large-cell Lymphoma 2Q25: 20 centers open in US + Canada Interim Data: 2H26 MOA: ITKi regulates plasticity/polarisation of PTCL CD4+ cells Reduces

Just downloaded the 9th #Dermatology Drug Development Summit Event Guide for Boston, November 18-20th Corvus Pharmaceutical $CRVS oral #ITK inhibitor #soquelitinib featured prominently in intro to conference and appears to be a key highlight of meeting thebostoncalendar.com/events/9th-der…

📰New paper: Inhibition of #ITK could offer new therapeutic strategy for #aplastic #anemia, a $6.7B/yr disease, high unmet need w/ very poor treatment options. Another potential indication for $CRVS #soquelitinib, increaseing TAM ⬆️ link.springer.com/article/10.100…

Nice summary/graphic of treatments for #IBD including: #S1PR #JAK #IL17 #IL23 #TNFa drugs After success of $ABVX in Ph 3 #UC, needs to be updated to add #Obefazimod which reduces the number of #Th17 cells/#IL17 produced by upregulating miR-124. New MOA ir.abivax.com/news-releases/…

#ITK inhibitors prevent pancreatic islet infiltration by T cells in #T1D New: #BCL6 #Tfh cells key role in T1D ITK inhibitors block #Tfh by suppressing the key Bcl-6 and promoting #Th1 factor #Tbet, skewing for Th1 Would love a study of $CRVS ITK inhibitor #soquelitinib in

Table of some pre-clinical/animal studies shows large potential of #ITK inhibition in Type 1 diabetes #T1D - reduced incidence 50%, delayed onset Large $20B market, unmet need ITKi modulation of T-cells across indications has potential to rival size of GLP1 drug market - $CRVS

Probability of $HOC.L $HCHDF buyout likely low due to large family ownership, but large valuation gap w/ peers makes it increasingly attractive target. Even a 50% premium (420p) is accretive for (4) miners: $PAAS $CDE $FRES.L $HL $FRES.L $PAAS $CDE have strong #LatAm overlap

Chart comparing bios Richard Miller founded including last 7 yrs share price + total returns before buyout. IDEC - 83x (#rituximab, $6.8B merger w/ $BIIB) Pharmacyclic $PCYC - 325x (#ibrutinib #BTK, $21B buyout $ABBV) Corvus $CRVS - 6.5x currently (#soquelitinib #ITK) Roadmap?

New Job at $CRVS: Associate Director Clinical Supply Management Getting ready for more and bigger drug trials⤵️ This kind of role is for bios in "growth mode" that are preparing for expansion of clinical pipeline and operations. corvuspharma.com/join-our-team/…

Fascinating new paper: "heightened immunoregulatory programs with #MASH progression" - #Th17 cells increase in liver + blood w/ increasing #fibrosis in liver - Exhausted CD8+ phenotype increased in liver with fibrosis, while CD8+ #TEMRA cell populations decreased w/ #steatosis

Opportunity for $CRVS #ITK inhibitor #soquelitinib to prevent key immune cell imbalances that emerge in #MASLD/#MASH progression + liver #fibrosis: Soquelitinib 1. Reduces #Th17 cells 2. Reverses CD8+ T-cell exhaustion 3. Increases #Tregs + CD8+ #TEMRA nature.com/articles/s4438…

⚡️New: Review of 14 studies highlights potential benefit of IL-17 and IL-23 inhibitors on #MASLD and liver #fibrosis in patients w/ #psoriasis who are at higher risk due to shared role of #Th17/#IL17 in the diseases, further strengthening connection. pmc.ncbi.nlm.nih.gov/articles/PMC12…